132 related articles for article (PubMed ID: 32336193)
1. CYP3A subfamily activity affects the equilibrium concentration of Phenazepam
Zastrozhin MS; Skryabin VY; Sorokin AS; Petukhov AE; Smirnov VV; Pankratenko EP; Grishina EA; Ryzhikova KA; Panov AS; Savchenko LM; Bryun EA; Sychev DA
Pharmacogenomics; 2020 May; 21(7):449-457. PubMed ID: 32336193
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder.
Zastrozhin MS; Antonenko AP; Nesterenko EV; Seyfullaeva LI; Mustafina VR; Esakova AP; Grishina EA; Sorokin AS; Skryabin VY; Savchenko LM; Bryun EA; Sychev DA
Drug Metab Pers Ther; 2018 Dec; 33(4):187-194. PubMed ID: 30325732
[TBL] [Abstract][Full Text] [Related]
3. Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder.
Zastrozhin MS; Skryabin VY; Smirnov VV; Petukhov AE; Pankratenko EP; Zastrozhina AK; Grishina EA; Ryzhikova KA; Bure IV; Golovinskii PA; Koporov SG; Bryun EA; Sychev DA
Gene; 2020 May; 739():144513. PubMed ID: 32112986
[TBL] [Abstract][Full Text] [Related]
4. Effects of
Zastrozhin MS; Skryabin VY; Torrado M; Petrovna A; Sorokin AS; Grishina EA; Ryzhikova KA; Bedina IA; Buzik OZ; Chumakov EM; Savchenko LM; Brun EA; Sychev DA
Pharmacogenomics; 2020 Jan; 21(2):111-123. PubMed ID: 31957548
[No Abstract] [Full Text] [Related]
5. Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder.
Zastrozhin MS; Efimova AV; Skryabin V; Smirnov VV; Petukhov AE; Pankratenko EP; Pozdniakov SA; Kaverina EV; Klepikov DA; Grishina EA; Ryzhikova KA; Bure IV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2021 Nov; 51(4):87-104. PubMed ID: 34887601
[TBL] [Abstract][Full Text] [Related]
6. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers.
Zastrozhin MS; Sorokin AS; Agibalova TV; Grishina EA; Antonenko AР; Rozochkin IN; Duzhev DV; Skryabin VY; Galaktionova TE; Barna IV; Orlova AV; Aguzarov AD; Savchenko LM; Bryun EA; Sychev DA
Hum Psychopharmacol; 2018 Nov; 33(6):e2677. PubMed ID: 30357930
[TBL] [Abstract][Full Text] [Related]
7. Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies.
Ivashchenko DV; Rudik AV; Poloznikov AA; Nikulin SV; Smirnov VV; Tonevitsky AG; Bryun EA; Sychev DA
Drug Metab Pers Ther; 2018 Jun; 33(2):65-73. PubMed ID: 29727298
[TBL] [Abstract][Full Text] [Related]
8. Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.
Zastrozhin MS; Skryabin V; Smirnov V; Zastrozhina AK; Kaverina EV; Klepikov DA; Grishina EA; Ryzhikova KA; Bure IV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2021 Jan; 51(1):69-80. PubMed ID: 33897064
[TBL] [Abstract][Full Text] [Related]
9. Using the CYP3A Activity Evaluation to Predict the Efficacy and Safety of Diazepam in Patients With Alcohol Withdrawal Syndrome.
Skryabin VY; Zastrozhin MS; Grishina EA; Ryzhikova KA; Shipitsyn VV; V Barna I; Galaktionova TE; Ivanov AV; Sorokin AS; Bryun EA; Sychev DA
J Pharm Pract; 2022 Aug; 35(4):518-523. PubMed ID: 33622083
[TBL] [Abstract][Full Text] [Related]
10. Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.
Zastrozhin MS; Skryabin V; Smirnov V; Zastrozhina AK; Kaverina EV; Klepikov DA; Grishina EA; Ryzhikova KA; Bure IV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2021 Mar; 51(2):31-42. PubMed ID: 34092821
[TBL] [Abstract][Full Text] [Related]
11. Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.
Sychev DA; Zastrozhin MS; Miroshnichenko II; Baymeeva NV; Smirnov VV; Grishina EA; Ryzhikova KA; Mirzaev KB; Markov DD; Skryabin VY; Snalina NE; Nosikova PG; Savchenko LM; Bryun EA
Drug Metab Pers Ther; 2017 Sep; 32(3):129-136. PubMed ID: 28787271
[TBL] [Abstract][Full Text] [Related]
12. [Optimization of the treatment of anxiety disorders with selank].
Medvedev VE; Tereshchenko ON; Kost NV; Ter-Israelyan AY; Gushanskaya EV; Chobanu IK; Sokolov OY; Myasoedov NF
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(6):33-40. PubMed ID: 26356395
[TBL] [Abstract][Full Text] [Related]
13. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder.
Zastrozhin MS; Skryabin VY; Smirnov VV; Grishina EA; Ryzhikova KA; Chumakov EM; Bryun EA; Sychev DA
Can J Physiol Pharmacol; 2019 Aug; 97(8):781-785. PubMed ID: 31100205
[TBL] [Abstract][Full Text] [Related]
14. Benzodiazepine use in anxiety disordered patients with and without a history of alcoholism.
Mueller TI; Goldenberg IM; Gordon AL; Keller MB; Warshaw MG
J Clin Psychiatry; 1996 Feb; 57(2):83-9. PubMed ID: 8591974
[TBL] [Abstract][Full Text] [Related]
15. [Effect of phenazepam in various medicinal forms on psychophysical state of patients with anxiety disorders].
Neznamov GG; Dorofeeva OA; Teleshova ES; Siuniakov SA; Mametova LÉ
Eksp Klin Farmakol; 2011; 74(5):6-12. PubMed ID: 21809691
[TBL] [Abstract][Full Text] [Related]
16.
Skryabin VY; Franck J; Lauschke VM; Zastrozhin MS; Shipitsyn VV; Bryun EA; Sychev DA
Nord J Psychiatry; 2023 Jan; 77(1):73-76. PubMed ID: 35471917
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacological action on emotional sphere with phenazepam and caffeine changes preference of ethanol in Wistar male rats].
Kulagina KO; Egorov AY; Filatova EV
Zh Evol Biokhim Fiziol; 2014; 50(2):130-6. PubMed ID: 25486818
[TBL] [Abstract][Full Text] [Related]
18. [Subjective evaluation of the effect of single test doses of phenazepam and placebo in patients with anxiety disorders: a relationship with objective pharmaco-electroencephalography characteristics].
Neznamov GG; Bochkarev VK
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(9):53-60. PubMed ID: 30335073
[TBL] [Abstract][Full Text] [Related]
19. [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].
Medvedev VE; Tereshchenko ON; Israelian AIu; Chobanu IK; Kost NV; Sokolov OIu; Miasoedov NF
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(7):17-22. PubMed ID: 25176261
[TBL] [Abstract][Full Text] [Related]
20. EFFECT OF CARBAMAZEPINE ON THE ACTIVITY OF CYP3A4 ISOENZYME IN PATIENTS WITH ALCOHOL ADDICTION.
Zastrozhin MS; Simirnov VV; Sychev DA; Savchenko LM; Bryun EA; Gushchina YS; Matis OA; Nechaev MO; Naumova AG
Eksp Klin Farmakol; 2016; 79(10):18-21. PubMed ID: 30085479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
